Business Context and Reporting Period
This Form 8-K was filed by EyePoint Pharmaceuticals, Inc. (now EyePoint, Inc.) on December 8, 2025. The report details a corporate name change effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance changes and does not contain financial performance data.
Material Changes
- Corporate Name Change: The Company's name was officially changed from "EyePoint Pharmaceuticals, Inc." to "EyePoint, Inc."
- Legal Documentation: A Certificate of Amendment to the Certificate of Incorporation and an amendment to the By-laws were filed to reflect the new name.
- Stock Trading: The common stock continues to trade on the Nasdaq Global Market under the ticker symbol "EYPT."
- Security Identifiers: The CUSIP number (30233G209) remains unchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report explicitly states that the name change does not affect the rights of the Company's security holders.
Investor Verification Checklist
- Confirm the new legal name "EyePoint, Inc." is reflected in all future filings and communications.
- Verify that the ticker symbol "EYPT" and CUSIP "30233G209" remain active and unchanged on the Nasdaq Global Market.
- Review the attached Certificate of Amendment (Exhibit 3.1) and By-laws Amendment (Exhibit 3.2) for any non-name-related provisions, though the filing states no other changes were made.